What do systematic reviews say?

Non‐steroidal mineralocorticoid receptor antagonist vs selective aldosterone antagonist

Non‐steroidal mineralocorticoid receptor antagonist showed no clear difference in hyperkalaemia compared with selective aldosterone antagonist (low certainty).

• Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic… 2020 · Cochrane Headline outcomes only
  RR 0.89 [0.45, 1.77]
  1 study · 1023 participants
  Low

Non‐steroidal mineralocorticoid receptor antagonist vs selective aldosterone antagonist

Non‐steroidal mineralocorticoid receptor antagonist showed no clear difference in death compared with selective aldosterone antagonist (low certainty).

• Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic… 2020 · Cochrane Headline outcomes only
  RR 0.7 [0.31, 1.55]
  1 study · 1055 participants
  Low

Non‐steroidal mineralocorticoid receptor antagonist vs selective aldosterone antagonist

The review found no eligible studies for this question.

• Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic… 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Non‐steroidal mineralocorticoid receptor antagonist vs selective aldosterone antagonist

Non‐steroidal mineralocorticoid receptor antagonist showed no clear difference in doubling serum creatinine compared with selective aldosterone antagonist (low certainty).

• Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic… 2020 · Cochrane Headline outcomes only
  RR 0.8 [0.03, 19.51]
  1 study · 1055 participants
  Low

Non‐steroidal mineralocorticoid receptor antagonist vs selective aldosterone antagonist

The review found no eligible studies for this question.

• Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic… 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Non‐steroidal mineralocorticoid receptor antagonist vs selective aldosterone antagonist

The review found no eligible studies for this question.

• Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic… 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Non‐steroidal mineralocorticoid receptor antagonist vs selective aldosterone antagonist

The review found no eligible studies for this question.

• Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic… 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Aldosterone antagonists vs placebo or usual care

Aldosterone antagonists showed no clear difference in doubling serum creatinine compared with placebo or standard care (low certainty).

• Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic… 2020 · Cochrane Headline outcomes only
  RR 1.3 [0.69, 2.44]
  2 studies · 875 participants
  Low

Aldosterone antagonists vs placebo or usual care

Aldosterone antagonists probably leads to higher AKI compared with placebo or standard care (moderate certainty).

• Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic… 2020 · Cochrane Headline outcomes only
  RR 2.04 [1.05, 3.97]
  5 studies · 1446 participants
  Moderate

Aldosterone antagonists vs placebo or usual care

• Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic… 2020 · Cochrane Headline outcomes only
  no estimate extracted
  14 studies · 1193 participants
  Very low

Aldosterone antagonists vs placebo or usual care

• Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic… 2020 · Cochrane Headline outcomes only
  no estimate extracted
  12 studies · 1144 participants
  Low

Aldosterone antagonists vs diuretics

The review found no eligible studies for this question.

• Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic… 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: ECM vs other enteric‐coated preparations

• Pancreatic enzyme replacement therapy for people with cystic fibrosis 2020 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 56 participants
  Very low

Summary of findings: ECM vs other enteric‐coated preparations

• Pancreatic enzyme replacement therapy for people with cystic fibrosis 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 45 participants
  Very low

Summary of findings: ECM vs other enteric‐coated preparations

The review found no eligible studies for this question.

• Pancreatic enzyme replacement therapy for people with cystic fibrosis 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: ECM vs other enteric‐coated preparations

• Pancreatic enzyme replacement therapy for people with cystic fibrosis 2020 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 56 participants
  Very low

Summary of findings: ECM vs other enteric‐coated preparations

• Pancreatic enzyme replacement therapy for people with cystic fibrosis 2020 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 56 participants
  Very low

Summary of findings: ECM vs other enteric‐coated preparations

The review found no eligible studies for this question.

• Pancreatic enzyme replacement therapy for people with cystic fibrosis 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: ECM vs other enteric‐coated preparations

The review found no eligible studies for this question.

• Pancreatic enzyme replacement therapy for people with cystic fibrosis 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Pine bark extract vs placebo

The review found no eligible studies for this question.

• Pine bark (Pinus spp.) extract for treating chronic disorders 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found